Camlin Fine Sciences Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Camlin Fine Sciences reported its Q1 FY26 (quarter ended June 30, 2025) unaudited results. Consolidated revenue grew about 11% year-on-year to Rs. 42,355 lakh from Rs. 38,085 lakh, while standalone revenue rose around 5% to Rs. 19,144 lakh from Rs. 18,191 lakh. The company stayed in the red, posting a consolidated net loss of Rs. 1,068 lakh (versus a Rs. 3,465 lakh loss in Q1 FY25) and a standalone net loss of Rs. 1,068 lakh (versus Rs. 1,368 lakh). The board approved the re-appointment of Mr. Joseph Conrad D'Souza as an Independent Director for a second 5-year term (subject to shareholder approval via postal ballot), appointed Mr. Hari Rajmohan as alternate director, and gave CFO Santosh Parab additional charge of HR after the resignation of the HR head. The Italy Diphenol and China Vanillin facilities continue to be classified as discontinued operations following earlier impairments.
Year-on-year revenue growth and a narrower loss are mildly positive, but the company remains loss-making at both standalone and consolidated levels, and EBITDA margin has clearly compressed. Shareholders should watch for sustained profitability and successful resolution of the discontinued overseas units before sentiment improves.